GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Verici Dx PLC (LSE:VRCI) » Definitions » Total Equity

Verici Dx (LSE:VRCI) Total Equity : £7.75 Mil (As of Jun. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Verici Dx Total Equity?

Verici Dx's total equity for the quarter that ended in Jun. 2024 was £7.75 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Verici Dx Total Equity Historical Data

The historical data trend for Verici Dx's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verici Dx Total Equity Chart

Verici Dx Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Total Equity
14.60 9.01 9.45 2.81

Verici Dx Semi-Annual Data
Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Total Equity Get a 7-Day Free Trial 14.30 9.45 5.30 2.81 7.75

Verici Dx Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Verici Dx's Total Equity for the fiscal year that ended in Dec. 2023 is calculated as

Total Equity=Total Assets(Q: Dec. 2023 )-Total Liabilities(Q: Dec. 2023 )
=5.88-3.069
=2.81

Verici Dx's Total Equity for the quarter that ended in Jun. 2024 is calculated as

Total Equity=Total Assets(Q: Jun. 2024 )-Total Liabilities(Q: Jun. 2024 )
=9.515-1.765
=7.75

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Verici Dx Total Equity Related Terms

Thank you for viewing the detailed overview of Verici Dx's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Verici Dx Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Verici Dx PLC (LSE:VRCI) » Definitions » Total Equity
Comparable Companies
LSE:ABDX LSE:GDR LSE:GENI LSE:PRM LSE:LLAI LSE:AGL TMO DHR SHSE:603259 IQV IDXX A XSWX:LONN MTD ICLR LH ILMN DGX WAT EXAS
Traded in Other Exchanges
VRCDF:USA
Address
19 Stanwell Road, Avon House, Penarth, Cardiff, GBR, CF64 2EZ
Website
https://www.vericidx.com
Verici Dx PLC is an immuno-diagnostics development company. The company is focused on developing diagnostics technologies that will help understand the outcomes of an organ transplant surgery. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; and Tuteva, a post-transplant diagnostic focused upon acute cellular rejection including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels. The business of the Group comprises a single activity, which of the development of prognostic and diagnostic tests for kidney transplant patients.

Verici Dx Headlines

No Headlines